137 results about "Freund's adjuvant" patented technology

The present invention intends to provide a non-human animal model of Guillain-Barré syndrome, which can be obtained by immunizing FcγRIIB-gene-deficient non-human animal with ganglioside GQ1b, and a screening method of a therapeutic agent for Guillain-Barré syndrome using the non-human animal model. A mouse model of Guillain-Barré syndrome is generated by immunizing FcγRIIB-gene-deficient mice with gangliosides GM1, GM2, GD1a, and GQ1b together with Freund's adjuvant every three weeks four times in total.

The invention discloses a method of preparing a bombyx mori silk fibroin specific antibody by utilizing a characteristic dodecapeptide. The method comprises the following steps: synthesizing a polypeptide with a "CGYGAGAGAGYGA" sequence, coupling the polypeptide with keyhole limpet hemocyanin (KLH) so as to obtain a complete antigen; diluting the complete antigen with normal saline, mixing the diluted complete antigen with a complete Freund's adjuvant, carrying out an emulsion treatment so as to obtain primary immunized antigen emulsion, subjecting a rabbit to a primary immunization by using the primary immunized antigen emulsion, then subjecting the rabbit to a strengthened immunization, wherein the strengthened immunization uses a strengthened immunized antigen emulsion, which is prepared by the following steps: mixing the diluted complete antigen with an incomplete Freund's adjuvant, and then carrying out an emulsion treatment so as to obtain the target product; collecting the blood of the immunized rabbit, when the antiserum titer of rabbit arrives at 1 / 10000; making the blood blocks fully contract to completely separate out the antiserum, then collecting the antiserum, and subjecting the antiserum to a centrifugation treatment so as to obtain a supernate. The antibody prepared by the invention has a strong specificity, and can be used for detection and analysis of silk fibroin in textile, and the like.

An immunological response potentiation process is disclosed for synthetic or genetically engineered antigens having low immunogenicity. The antigen is embedded into biodegradable microparticles, and the antigen-loaded microparticles are dispersed in a biodegradable medium. When parenterally administered, the antigen-loaded microparticles trigger a potentiated antibody, TH-lymphocyte and Tc-lymphocyte response, as compared to an aqueous antigen solution. The extent of immunological potentiation is at least comparable with that attained by Incomplete Freund's adjuvant compositions. Linear B-TH-cell epitopes, linear Tc-cell epitopes, dimers and multimers of those epitopes, and mixtures thereof, are used as low immunogenicity antigens. The microparticles are based on biodegradable biopolymers such as polyester, polyanhydride, and polyorthoester. By mixing microparticles with different wettabilities, swellabilities, release and biodegradation times, the most intense and longest immunological potentiation is achieved. This process is useful for immunizing humans and animals against diseases caused by viruses, bacteria, protozoa or tumor cells.

This invention discloses means for obtaining immunogenic peptides, polypeptides, proteins, and their corresponding nucleic acid sequences, target cells with vaccine interest, or lysates thereof, without making structural changes in said antigens, through their association with Very Small Size Proteoliposomes. The object of the invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their lysates and Very Small Size Proteoliposomes (VSSP), which are formed by binding the Outer Membrane Protein Complex (OMPC) of Neisseria meningitidis with gangliosides, by means of hydrophobic links. Additionally, it is stated that these compositions can be formulated alone or in the form of emulsions with the Incomplete Freund's Adjuvant (IFA), and may also be lyophilized. The essence of the invention consists in describing compositions that triggers immunogenicity in low immunogenic antigens, such as growth factor receptors, without imparting structural changes therein. Particularly, this invention refers to preparation of immuno-stimulating compositions capable of generating antigen-specific immune responses, even in immuno-compromised hosts, such as those suffering form cancer or viral or bacterial chronic infections. In said patients, the administration of the vaccine compositions described in this invention has lead to the reestablishment of the functionality of the immune system. Vaccine compositions of this invention can be used to protect or treat infectious, or auto-immune diseases.

This invention discloses means for obtaining immunogenic peptides, polypeptides, proteins, and their corresponding nucleic acid sequences, target cells with vaccine interest, or lysates thereof, without making structural changes in said antigens, through their association with Very Small Size Proteoliposomes.The object of the invention is to provide immunogenic compositions containing peptides, polypeptides, proteins, their corresponding DNA sequences, cells or their lysates and Very Small Size Proteoliposomes (VSSP), which are formed by binding the Outer Membrane Protein Complex (OMPC) of Neisseria meningitidis with gangliosides, by means of hydrophobic links. Additionally, it is stated that these compositions can be formulated alone or in the form of emulsions with the Incomplete Freund's Adjuvant (IFA), and may also be lyophilized.The essence of the invention consists in describing compositions that triggers immunogenicity in low immunogenic antigens, such as growth factor receptors, without imparting structural changes therein. Particularly, this invention refers to preparation of immuno-stimulating compositions capable of generating antigen-specific immune responses, even in immuno-compromised hosts, such as those suffering form cancer or viral or bacterial chronic infections. In said patients, the administration of the vaccine compositions described in this invention has lead to the reestablishment of the functionality of the immune system. Vaccine compositions of this invention can be used to protect or treat infectious, or auto-immune diseases.

The invention relates to the field of animal virology and immunology, and provides an epitope vaccine for resisting A / B subgroup avian leucosis virus infection. The epitope vaccine is prepared by highly active recombinant protein His-cENV which is obtained through screening and purification after prokaryotic expression and a freund's adjuvant in a united manner, wherein the nucleotide sequence for encoding the recombinant protein His-cENV is shown as SEQ ID NO.1. Through the epitope vaccine, 7-day-old breeding poultry chicks are immune and can produce 1:128000 neutralizing antibodies. Vitro virus neutralization experiments and animal experiments show that the epitope vaccine can neutralize different ALV-A / B isolated strains, so that chicken flocks are effectively protected to resist the infection of ALV-A / B strains. Because the epitope vaccine is based on a multi-epitope antigen gene sequence which is originated form env, the defect of ALV-A / B virus variation is overcome, a new era of the ALV-A / B vaccine is opened, a new way of resisting the ALV-A / B infection is provided, and a technical support for preventing and controlling the ALV-A / B is provided.

The invention provides a yolk antibody oral preparation for treating piglet PED (porcine epidemic diarrhea). The yolk antibody oral preparation is characterized by containing a yolk antibody extracted from egg yolks collected after nonimmune laying hens are immunized with PEDV (porcine epidemic diarrhea virus) epidemic strain protective antigen gene COE protein. The invention further provides a preparation method of the oral preparation, comprising the steps: taking a current epidemic strain as a basis, performing prokaryotic expression and purification on PEDV protective antigen gene COE, so as to obtain target protein; preparing immunogen with freund's adjuvant, and then inoculating the nonimmune laying hens; collecting eggs after immunity, and extracting a yolk antibody from yolk; and preparing the safe and efficient yolk antibody oral preparation from the yolk antibody. The yolk antibody oral preparation disclosed by the invention can be used for effectively treating diseased piglets with PED, and meanwhile, the yolk antibody oral preparation can be used for preventing un-infected piglets from getting infected in the same group. The oral preparation is simple in preparation technique, and is suitable for bulk production and clinical use.

The invention discloses a medicinal composition for treating rheumatoid arthritis. The medicinal composition is prepared from the following Chinese herbal medicines in part by weight: 2.5 to 10 parts of periploca forrestii schltr, 1 to 4 parts of gentiana macrophylla and 1 to 4 parts of yanhusuo. The invention also discloses a preparation method and a quality detection method for the medicinal composition, and application of the medicinal composition. Through reasonable compatibility of the periploca forrestii schltr, the gentiana macrophylla and the yanhusuo, the medicinal composition has an obvious curative effect on arthritis induced by a complete freund adjuvant, good anti-inflammatory and analgesic effects, a better pharmaceutical effect compared with the simple medicinal material and the medicine which is prepared from other Chinese herbal medicines, and small toxic and side effects and achieves a synergistic effect. The modern pharmological study proves that the medicinal composition can safely and effectively treat rheumatoid arthritis and provides a new choice for clinical treatment.